AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis ...Middle East

The marketing authorization for SKYRIZI® (risankizumab) marks its fourth approved indication in the European Union The approval is supported by data from two pivotal Phase 3 trials: The INSPIRE induction trial1 and COMMAND maintenance trial2 In both trials, SKYRIZI achieved the primary...

Hence then, the article about abbvie announces european commission approval of skyrizi risankizumab for the treatment of adults with moderately to severely active ulcerative colitis was published today ( Friday 26/07/2024 - 09:08 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis )

Also on site :

• LIVE: Iran announces live-fire naval drills near US warships amid tensions
• Venezuela’s acting President Delcy Rodriguez announces prisoner amnesty
• 'The Pitt': What Is Worse Than MRSA? Dr. Langdon's Latest Patient Diagnosis, Explained